J&J acquires experimental skin disorder drug for $1.25 billion
On Tuesday, J&J finalized a deal to obtain the rights to an innovative treatment for skin conditions from Numab Therapeutics, a privately held company, in a transaction valued at approximately $1.25 billion, marking its second significant agreement this month focused on addressing eczema.
Judge rejects key expert in paraquat lawsuits, tosses first cases set for trial
Paraquat lawsuits, An expert witness who is vital to cases claiming that Syngenta’s herbicide, paraquat, causes Parkinson’s disease is not able to be called in to testify in the courtroom the way a federal judge decided Wednesday, dissolving the first four lawsuits involving the product, which were scheduled to be tried.
Ozempic lead counsel selection process is model for judges in big cases
In March, during hearings that were the first hearing, which opened another tab in the ongoing litigation involving the alleged unreported side effects of Ozempic along with other diet medications, attorneys for plaintiffs told the Philadelphia federal court judge they had already decided on a team of four attorneys to head the mass tort lawsuit.
The Pros and Cons of Social Media on Mental Health
Social media is a part of everyday life, and this trend will not change anytime soon. 72% of Americans use at least one form of social media, and this trend is expected to continue as social media grows in popularity.
More than 250 websites selling fake Ozempic & other weight loss drugs reported by anti-counterfeit firm
BrandShield, a cybersecurity company, has shut down over 250 sites offering counterfeit versions of popular weight loss and diabetes medications under the GLP-1 category such as Ozempic, BrandShield’s CEO Yoav Keren told Reuters.
Column: Ozempic litigation’s leadership spat spotlights lawyers’ self-selection
A squabble playing out in consolidated litigation against Ozempic, Wegovy and Mounjaro drugmakers highlights important questions about how courts should decide who will lead these sweeping cases.
Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts
Sanofi opened a new tab and has signed an accord in principle that will resolve 4,000 U.S. lawsuits linking the discontinuation of the heartburn medication Zantac and cancer. The pharmaceutical company announced this on Wednesday.
Johnson & Johnson gets a new opportunity to contest science in talc litigation
Johnson & Johnson will get an overhaul in its fight in the face of more than 50k lawsuits alleging the famous baby powder could cause cancer of the ovaries.
Johnson & Johnson faces class action over employees’ prescription drug costs
Johnson & Johnson was hit by a class action lawsuit on Monday. The health plans for employees do not negotiate lower prices on prescription drugs, which cost employees thousands of dollars in overpayments to generic drugs.
Novo Nordisk settles with Florida spa, clinic over knockoff Ozempic
Novo Nordisk opens a new tab and has reached a settlement with a medical spa and a weight loss clinic in Florida, which was accused of promoting counterfeit versions of the weight loss and diabetes medicines, the Danish drugmaker said on Friday.
